Nexalin Technology Inc. (NXL)
| Bid | 3.21 |
| Market Cap | 41.74M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.65 |
| PE Ratio (ttm) | -4.99 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.29 |
| Volume | 131,095 |
| Avg. Volume (20D) | 449,467 |
| Open | 3.26 |
| Previous Close | 3.30 |
| Day's Range | 3.15 - 3.27 |
| 52-Week Range | 0.30 - 4.49 |
| Beta | undefined |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...
Analyst Forecast
According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $3, which is a decrease of -7.55% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
